Longitudinal Outcomes of Dolutegravir-based Antiretroviral Therapy in a Large Nigerian Programmatic HIV Cohort, 2017–2019

Clicks: 32
ID: 326854
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #60 of 316 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 316 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract In a retrospective Nigerian cohort of 33,982 PLHIV initiating or switching to TLD, virological suppression reached 80–82% among participants with available viral load data and 63–65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.
Reference Key
openalex_W7204565319 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Adam Abdullahi, Edun Martin, Kwabena Asare, Haruna Wisso Abdullahi, Ibrahim Musa Kida, Sophia Osawe, James Onyemata, Sani Aliyu, Manhattan Charurat, Fati Murtala-Ibrahim, Victor Adamu, Helen Omuh, Tim Efuntoye, Patrick Dakum, Alashʼle Abimiku, Ravindra K. Gupta
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag549
URL
https://doi.org/10.1093/ofid/ofag549
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.